Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infections

In brief

This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection among men and transgender (TG) persons who have sex with men, in North America, South America, and Switzerland.

Key facts

Study ID

NCT02716675

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

2699

Starts

2016-04-06

Expected to finish

2020-12-01

Last updated by the study team

2022-02-23

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• General and Demographic Criteria
• Age of 18 to 50 years
• Access to a participating clinical research site (CRS) and willingness to be followed for the planned duration of the study
• Ability and willingness to provide informed consent
• Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first infusion with verbal demonstration of understanding of all questionnaire items answered incorrectly
• Agrees not to enroll in another study of an investigational research agent for the duration of the participant's trial participation
• Good general health as shown by medical history, physical exam, and screening laboratory tests
• HIV-Related Criteria
• Willingness to receive HIV test results
• Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling
• Persons born Male or identifying as Transgender (TG) (male-to-female or female-to-male, see HVTN 704/HPTN 085 SSP) who, in the 6 months prior to randomization, experienced 1 or both of the following HIV risk criteria:
• Condomless anal intercourse with 1 or more male or transgender partner(s)
• Anal intercourse with 2 or more male or transgender partners
• Male-to-female and female-to-male TG volunteers are eligible. Receipt of hormonal therapy does not make a TG volunteer ineligible.
• Volunteers who have been in a mutually monogamous relationship with an HIV-1 seronegative partner for greater than 1 year are excluded.
• Laboratory Inclusion Values:
• Hematology
• Hemoglobin (Hgb) greater than or equal to 10.5 g/dL for volunteers who were born female, greater than or equal to 13.0 g/dL for volunteers who were born male (greater than or equal to 12.0 g/dL for transgender women taking feminizing hormones [e.g., anti-androgens, estrogens])
• Platelets greater than or equal to 100,000 cells/mm\^3
• Chemistry
• Alanine aminotransferase (ALT) less than 2.5 times the institutional upper limit of normal and creatinine less than or equal to 1.25 times the institutional upper limit of normal
• Virology
• HIV uninfected, as defined in the SSP, within 30 days prior to enrollment
• Urine
• Negative, trace, or 1+ (30 g/L for semi-quantitative) urine protein by dipstick

You may not qualify if…

• General
• Investigational research agents received within 30 days before first infusion
• Body mass index (BMI) greater than or equal to 40
• Pregnant or breastfeeding
• Any reactive, indeterminate, or positive HIV test, even if subsequent testing indicates that the individual is not HIV infected, except as permitted by the HVTN 704/HPTN 085 Protocol Safety Review Team (PSRT).
• Vaccines
• HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 704/HPTN 085 PSRT will determine eligibility on a case-by-case basis.
• Immune System
• Serious adverse reactions to VRC01 formulation components such as sodium citrate, sodium chloride, and L-arginine hydrochloride, including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.
• Autoimmune disease, including Type I diabetes mellitus (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require consistent immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate reactogenicity and AE assessments)
• Immunodeficiency syndrome
• Clinically Significant Medical Conditions
• Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
• Any contraindication to repeated infusions or blood draws, including inability to establish venous access;
• A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period; or
• A condition or process for which signs or symptoms could be confused with reactions to VRC01.
• Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or infusion reactions, or a volunteer's ability to give informed consent
• Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
• Asthma, other than mild, well-controlled asthma
• Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
• Malignancy (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study)
• Seizure disorder: History of seizure(s) within past three years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
• History of hereditary angioedema, acquired angioedema, or idiopathic angioedema
• History of receiving transplantation of life-saving organs or tissues (includes heart, kidney, pancreas, lungs, liver, and intestines)
• Known hepatic or renal dysfunction

Where it is running

• Alabama CRS — Birmingham, Alabama, United States
• UCLA Vine Street Clinic CRS — Los Angeles, California, United States
• Bridge HIV CRS — San Francisco, California, United States
• George Washington Univ. CRS — Washington D.C., District of Columbia, United States
• The Ponce de Leon Center CRS — Atlanta, Georgia, United States
• The Hope Clinic of the Emory Vaccine Center CRS — Decatur, Georgia, United States
• Brigham and Women's Hospital Vaccine CRS (BWH VCRS) — Boston, Massachusetts, United States
• Fenway Health (FH) CRS — Boston, Massachusetts, United States
• New Jersey Medical School Clinical Research Center CRS — Newark, New Jersey, United States
• Harlem Prevention Center CRS — New York, New York, United States
• Columbia P&S CRS — New York, New York, United States
• New York Blood Center CRS — New York, New York, United States
• University of Rochester Vaccines to Prevent HIV Infection CRS — Rochester, New York, United States
• Bronx Prevention Research Center CRS — The Bronx, New York, United States
• Chapel Hill CRS — Chapel Hill, North Carolina, United States
• Case Clinical Research Site — Cleveland, Ohio, United States
• Penn Prevention CRS — Philadelphia, Pennsylvania, United States
• Vanderbilt Vaccine (VV) CRS — Nashville, Tennessee, United States
• Seattle Vaccine and Prevention CRS — Seattle, Washington, United States
• Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS — Rio de Janeiro, Brazil
• ACSA CRS — Iquitos, Maynas, Peru
• CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS — Bellavista, Provincia Constitucional del Callao, Peru
• Barranco CRS — Lima, Peru
• San Miguel CRS — Lima, Peru
• Via Libre CRS — Lima, Peru

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.